Log In
BCIQ
Print this Print this
 

L19-actinium 225

  Manage Alerts
Collapse Summary General Information
Company Philogen S.p.A.
DescriptionL19, a recombinant human antibody against the EDB domain of fibronectin, radiolabeled with actinium 225
Molecular Target
Mechanism of ActionRadiolabelled antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsAnti-angiogenesis for cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today